Table 4. Biochemical characteristics and survival of patients with Trousseau’s syndrome.
| Patient No. | Hb (g/dL) | Platelet (*104/ul) | D-dimer (ul/mL) | Alb (g/dL) | CEA (ng/mL) | CA19-9 (U/mL) | CA125 (U/mL) | Transesophageal echo | Treatment of cerebral infarction | OS of after Trousseau |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6.5 | 8.2 | 18.9 | 2.6 | 108.6 | 3,553.7 | 858.1 | Verrucae on M valve | Endovascular treatment | 1 month |
| 2 | 10.9 | 48.9 | 11.2 | 1.6 | 6.1 | 25.8 | ND | Not performed | Antithrombotic therapy | 2 months |
| 3 | 8.5 | 8 | ND | 3.3 | 4.9 | ND | ND | Verrucae on M valve | Endovascular treatment | 1 month |
| 4 | 10.9 | 10.4 | 2.5 | 3.9 | 358.5 | 31.3 | 155.5 | Not performed | Antithrombotic therapy | 6 months |
| 5 | 7.7 | 15.1 | 26.3 | 3.1 | ND | 50,000 | 538.5 | Verrucae on M valve | Endovascular treatment | 0 month |
| 6 | 7.9 | 10.9 | 31.6 | 3.1 | ND | 14 | 484.3 | Verrucae on M valve | Antithrombotic therapy | 1 month |
Alb, albumin; CEA, carcinoembryonic antigen; Hb, hemoglobin; CA125, cancer antigen 125; CA19-9, carbohydrate antigen 19-9; ND, no data; OS, overall survival.